Date: 2011-11-04
Type of information: Company acquisition
Acquired company: Cellartis (Sweden)
Acquiring company: Cellectis (France)
Amount: € 30 million in shares and cash
Terms: On September 15, 2011, Cellectis, the French genome engineering specialist, has announced the signing of a contract for the acquisition of Cellartis, the European leader in stem cell-derived in vitro R&D tools. This acquisition, which is subject to the closing of the related financing, would enable Cellectis to become the world leader in stem cell-derived in vitro R&D tools and related technologies. At the same time, in order to finance the cash component of the acquisition of Cellartis and to accelerate the development of its other businesses, Cellectis will raise €50 million from the FSI and Pierre Bastid.
A general meeting of Cellectis shareholders shall be convened late October 2011 in order to vote on these transactions, which remain subject to its approval and to prevailing market conditions.
On November 4, 2011, Cellectis has announced the final completion of the acquisition of Cellartis and the resulting issue of 1,933,333 Cellectis shares to the former Cellartis’ shareholders, as well as the final completion of the issue of 6,250,000 convertible bonds for €50 million, evenly subscribed by the French strategic investment fund (FSI) and Mr. Pierre Bastid.
Details:
Related: Stem cells
